Regan Martin
Nurse Practitioner · Joplin, MONPI 1467833871
Payments from drug & device makers
Across 228 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$727
- AstraZeneca$590
- AbbVie$430
- Amgen$325
- Abbott$213
- Lilly USA, LLC$207
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $727 |
| AstraZeneca | 30 | $590 |
| AbbVie | 29 | $430 |
| Amgen | 28 | $325 |
| Abbott | 12 | $213 |
| Lilly USA, LLC | 12 | $207 |
| Dexcom, Inc. | 10 | $149 |
| GSK | 8 | $112 |
| Pfizer | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $65 |
| Astellas Pharma US Inc | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Bayer | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $47 |
| Biogen | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Merck | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Exact Sciences | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 2 | $8 |
How this compares
$3,512 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $202,641 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $110,025 |
| TrulicityDulaglutide | 52 | $75,000 |
| XifaxanRifaximin | 12 | $44,701 |
| LinzessLinaclotide | 49 | $41,336 |
| MyrbetriqMirabegron | 34 | $41,079 |
| JardianceEmpagliflozin | 36 | $40,818 |
| EliquisApixaban | 38 | $40,316 |
| OzempicSemaglutide | 42 | $39,875 |
| FarxigaDapagliflozin Propanediol | 36 | $36,223 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $30,119 |
| XareltoRivaroxaban | 28 | $27,456 |
| JanuviaSitagliptin Phosphate | 27 | $22,057 |
| VascepaIcosapent Ethyl | 47 | $21,818 |
| Repatha SureclickEvolocumab | 11 | $17,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $207 | $277,641215 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $112 | $141,739173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $590 | $72,15686 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $34 | $51,69350 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $44,70112 claims |
| AbbVieLinzess | $430 | $41,33649 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $41,07934 claims |
| PfizerEliquis | $99 | $40,31638 claims |
| Novo NordiskOzempic | $727 | $39,87542 claims |
| MerckJanuvia, Belsomra | $34 | $34,04754 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $3,663529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Joplin
- Benjamin LongJoplin$9K
- Vanessa JarrettJoplin$9K
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.